Results from the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial will be presented at 4:30 p.m. Sunday in W-3001 (West, Level 3). ADAMeetingNews.org caught up with REWIND study co-chair Hertzel C. Gerstein, MD, MSc, FRCPC, who discusses the study’s objective and significance.
Beginning soon: Once-Weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial
